Industry Research Reports

Home > Reports > Medical Care > Global Viral Vectors Gene Therapy Market Research Report 2025

Global Viral Vectors Gene Therapy Market Research Report 2025

Industry: Medical Care

Published Date: 2025-01-13

Pages: 84 Pages

Report ld: 3494646

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global market for Viral Vectors Gene Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Viral Vectors Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors Gene Therapy.

The Viral Vectors Gene Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Viral Vectors Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Viral Vectors Gene Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

MARKET SEGMENTATION

By Company

Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Biogen
Sarepta Therapeutics
Gilead Sciences

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Retro Viral Vectors
Adeno-associated Virus Vectors
Other Viral Vectors

Segment by Application

In Vivo
Ex Vivo

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Viral Vectors Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Viral Vectors Gene Therapy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Retro Viral Vectors

1.2.3 Adeno-associated Virus Vectors

1.2.4 Other Viral Vectors

1.3 Market by Application

1.3.1 Global Viral Vectors Gene Therapy Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 In Vivo

1.3.3 Ex Vivo

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Viral Vectors Gene Therapy Market Perspective (2020-2031)

2.2 Global Viral Vectors Gene Therapy Growth Trends by Region

2.2.1 Global Viral Vectors Gene Therapy Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Viral Vectors Gene Therapy Historic Market Size by Region (2020-2025)

2.2.3 Viral Vectors Gene Therapy Forecasted Market Size by Region (2026-2031)

2.3 Viral Vectors Gene Therapy Market Dynamics

2.3.1 Viral Vectors Gene Therapy Industry Trends

2.3.2 Viral Vectors Gene Therapy Market Drivers

2.3.3 Viral Vectors Gene Therapy Market Challenges

2.3.4 Viral Vectors Gene Therapy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Viral Vectors Gene Therapy Players by Revenue

3.1.1 Global Top Viral Vectors Gene Therapy Players by Revenue (2020-2025)

3.1.2 Global Viral Vectors Gene Therapy Revenue Market Share by Players (2020-2025)

3.2 Global Viral Vectors Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Viral Vectors Gene Therapy Revenue

3.4 Global Viral Vectors Gene Therapy Market Concentration Ratio

3.4.1 Global Viral Vectors Gene Therapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Viral Vectors Gene Therapy Revenue in 2024

3.5 Global Key Players of Viral Vectors Gene Therapy Head office and Area Served

3.6 Global Key Players of Viral Vectors Gene Therapy, Product and Application

3.7 Global Key Players of Viral Vectors Gene Therapy, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Viral Vectors Gene Therapy Breakdown Data by Type

4.1 Global Viral Vectors Gene Therapy Historic Market Size by Type (2020-2025)

4.2 Global Viral Vectors Gene Therapy Forecasted Market Size by Type (2026-2031)

5 Viral Vectors Gene Therapy Breakdown Data by Application

5.1 Global Viral Vectors Gene Therapy Historic Market Size by Application (2020-2025)

5.2 Global Viral Vectors Gene Therapy Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Viral Vectors Gene Therapy Market Size (2020-2031)

6.2 North America Viral Vectors Gene Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Viral Vectors Gene Therapy Market Size by Country (2020-2025)

6.4 North America Viral Vectors Gene Therapy Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Viral Vectors Gene Therapy Market Size (2020-2031)

7.2 Europe Viral Vectors Gene Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Viral Vectors Gene Therapy Market Size by Country (2020-2025)

7.4 Europe Viral Vectors Gene Therapy Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Viral Vectors Gene Therapy Market Size (2020-2031)

8.2 Asia-Pacific Viral Vectors Gene Therapy Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Viral Vectors Gene Therapy Market Size by Region (2020-2025)

8.4 Asia-Pacific Viral Vectors Gene Therapy Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Viral Vectors Gene Therapy Market Size (2020-2031)

9.2 Latin America Viral Vectors Gene Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Viral Vectors Gene Therapy Market Size by Country (2020-2025)

9.4 Latin America Viral Vectors Gene Therapy Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Viral Vectors Gene Therapy Market Size (2020-2031)

10.2 Middle East & Africa Viral Vectors Gene Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Viral Vectors Gene Therapy Market Size by Country (2020-2025)

10.4 Middle East & Africa Viral Vectors Gene Therapy Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Amgen

11.1.1 Amgen Company Details

11.1.2 Amgen Business Overview

11.1.3 Amgen Viral Vectors Gene Therapy Introduction

11.1.4 Amgen Revenue in Viral Vectors Gene Therapy Business (2020-2025)

11.1.5 Amgen Recent Development

11.2 Novartis

11.2.1 Novartis Company Details

11.2.2 Novartis Business Overview

11.2.3 Novartis Viral Vectors Gene Therapy Introduction

11.2.4 Novartis Revenue in Viral Vectors Gene Therapy Business (2020-2025)

11.2.5 Novartis Recent Development

11.3 Orchard Therapeutics

11.3.1 Orchard Therapeutics Company Details

11.3.2 Orchard Therapeutics Business Overview

11.3.3 Orchard Therapeutics Viral Vectors Gene Therapy Introduction

11.3.4 Orchard Therapeutics Revenue in Viral Vectors Gene Therapy Business (2020-2025)

11.3.5 Orchard Therapeutics Recent Development

11.4 Spark Therapeutics

11.4.1 Spark Therapeutics Company Details

11.4.2 Spark Therapeutics Business Overview

11.4.3 Spark Therapeutics Viral Vectors Gene Therapy Introduction

11.4.4 Spark Therapeutics Revenue in Viral Vectors Gene Therapy Business (2020-2025)

11.4.5 Spark Therapeutics Recent Development

11.5 Agc Biologics

11.5.1 Agc Biologics Company Details

11.5.2 Agc Biologics Business Overview

11.5.3 Agc Biologics Viral Vectors Gene Therapy Introduction

11.5.4 Agc Biologics Revenue in Viral Vectors Gene Therapy Business (2020-2025)

11.5.5 Agc Biologics Recent Development

11.6 Anges

11.6.1 Anges Company Details

11.6.2 Anges Business Overview

11.6.3 Anges Viral Vectors Gene Therapy Introduction

11.6.4 Anges Revenue in Viral Vectors Gene Therapy Business (2020-2025)

11.6.5 Anges Recent Development

11.7 Bluebird Bio

11.7.1 Bluebird Bio Company Details

11.7.2 Bluebird Bio Business Overview

11.7.3 Bluebird Bio Viral Vectors Gene Therapy Introduction

11.7.4 Bluebird Bio Revenue in Viral Vectors Gene Therapy Business (2020-2025)

11.7.5 Bluebird Bio Recent Development

11.8 Jazz Pharmaceuticals

11.8.1 Jazz Pharmaceuticals Company Details

11.8.2 Jazz Pharmaceuticals Business Overview

11.8.3 Jazz Pharmaceuticals Viral Vectors Gene Therapy Introduction

11.8.4 Jazz Pharmaceuticals Revenue in Viral Vectors Gene Therapy Business (2020-2025)

11.8.5 Jazz Pharmaceuticals Recent Development

11.9 Dynavax Technologies

11.9.1 Dynavax Technologies Company Details

11.9.2 Dynavax Technologies Business Overview

11.9.3 Dynavax Technologies Viral Vectors Gene Therapy Introduction

11.9.4 Dynavax Technologies Revenue in Viral Vectors Gene Therapy Business (2020-2025)

11.9.5 Dynavax Technologies Recent Development

11.10 Biogen

11.10.1 Biogen Company Details

11.10.2 Biogen Business Overview

11.10.3 Biogen Viral Vectors Gene Therapy Introduction

11.10.4 Biogen Revenue in Viral Vectors Gene Therapy Business (2020-2025)

11.10.5 Biogen Recent Development

11.11 Sarepta Therapeutics

11.11.1 Sarepta Therapeutics Company Details

11.11.2 Sarepta Therapeutics Business Overview

11.11.3 Sarepta Therapeutics Viral Vectors Gene Therapy Introduction

11.11.4 Sarepta Therapeutics Revenue in Viral Vectors Gene Therapy Business (2020-2025)

11.11.5 Sarepta Therapeutics Recent Development

11.12 Gilead Sciences

11.12.1 Gilead Sciences Company Details

11.12.2 Gilead Sciences Business Overview

11.12.3 Gilead Sciences Viral Vectors Gene Therapy Introduction

11.12.4 Gilead Sciences Revenue in Viral Vectors Gene Therapy Business (2020-2025)

11.12.5 Gilead Sciences Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Viral Vectors Gene Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Retro Viral Vectors

Table 3. Key Players of Adeno-associated Virus Vectors

Table 4. Key Players of Other Viral Vectors

Table 5. Global Viral Vectors Gene Therapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Viral Vectors Gene Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Viral Vectors Gene Therapy Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Viral Vectors Gene Therapy Market Share by Region (2020-2025)

Table 9. Global Viral Vectors Gene Therapy Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Viral Vectors Gene Therapy Market Share by Region (2026-2031)

Table 11. Viral Vectors Gene Therapy Market Trends

Table 12. Viral Vectors Gene Therapy Market Drivers

Table 13. Viral Vectors Gene Therapy Market Challenges

Table 14. Viral Vectors Gene Therapy Market Restraints

Table 15. Global Viral Vectors Gene Therapy Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Viral Vectors Gene Therapy Market Share by Players (2020-2025)

Table 17. Global Top Viral Vectors Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vectors Gene Therapy as of 2024)

Table 18. Ranking of Global Top Viral Vectors Gene Therapy Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Viral Vectors Gene Therapy Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Viral Vectors Gene Therapy, Headquarters and Area Served

Table 21. Global Key Players of Viral Vectors Gene Therapy, Product and Application

Table 22. Global Key Players of Viral Vectors Gene Therapy, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Viral Vectors Gene Therapy Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Viral Vectors Gene Therapy Revenue Market Share by Type (2020-2025)

Table 26. Global Viral Vectors Gene Therapy Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Viral Vectors Gene Therapy Revenue Market Share by Type (2026-2031)

Table 28. Global Viral Vectors Gene Therapy Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Viral Vectors Gene Therapy Revenue Market Share by Application (2020-2025)

Table 30. Global Viral Vectors Gene Therapy Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Viral Vectors Gene Therapy Revenue Market Share by Application (2026-2031)

Table 32. North America Viral Vectors Gene Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Viral Vectors Gene Therapy Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Viral Vectors Gene Therapy Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Viral Vectors Gene Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Viral Vectors Gene Therapy Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Viral Vectors Gene Therapy Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Viral Vectors Gene Therapy Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Viral Vectors Gene Therapy Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Viral Vectors Gene Therapy Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Viral Vectors Gene Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Viral Vectors Gene Therapy Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Viral Vectors Gene Therapy Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Viral Vectors Gene Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Viral Vectors Gene Therapy Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Viral Vectors Gene Therapy Market Size by Country (2026-2031) & (US$ Million)

Table 47. Amgen Company Details

Table 48. Amgen Business Overview

Table 49. Amgen Viral Vectors Gene Therapy Product

Table 50. Amgen Revenue in Viral Vectors Gene Therapy Business (2020-2025) & (US$ Million)

Table 51. Amgen Recent Development

Table 52. Novartis Company Details

Table 53. Novartis Business Overview

Table 54. Novartis Viral Vectors Gene Therapy Product

Table 55. Novartis Revenue in Viral Vectors Gene Therapy Business (2020-2025) & (US$ Million)

Table 56. Novartis Recent Development

Table 57. Orchard Therapeutics Company Details

Table 58. Orchard Therapeutics Business Overview

Table 59. Orchard Therapeutics Viral Vectors Gene Therapy Product

Table 60. Orchard Therapeutics Revenue in Viral Vectors Gene Therapy Business (2020-2025) & (US$ Million)

Table 61. Orchard Therapeutics Recent Development

Table 62. Spark Therapeutics Company Details

Table 63. Spark Therapeutics Business Overview

Table 64. Spark Therapeutics Viral Vectors Gene Therapy Product

Table 65. Spark Therapeutics Revenue in Viral Vectors Gene Therapy Business (2020-2025) & (US$ Million)

Table 66. Spark Therapeutics Recent Development

Table 67. Agc Biologics Company Details

Table 68. Agc Biologics Business Overview

Table 69. Agc Biologics Viral Vectors Gene Therapy Product

Table 70. Agc Biologics Revenue in Viral Vectors Gene Therapy Business (2020-2025) & (US$ Million)

Table 71. Agc Biologics Recent Development

Table 72. Anges Company Details

Table 73. Anges Business Overview

Table 74. Anges Viral Vectors Gene Therapy Product

Table 75. Anges Revenue in Viral Vectors Gene Therapy Business (2020-2025) & (US$ Million)

Table 76. Anges Recent Development

Table 77. Bluebird Bio Company Details

Table 78. Bluebird Bio Business Overview

Table 79. Bluebird Bio Viral Vectors Gene Therapy Product

Table 80. Bluebird Bio Revenue in Viral Vectors Gene Therapy Business (2020-2025) & (US$ Million)

Table 81. Bluebird Bio Recent Development

Table 82. Jazz Pharmaceuticals Company Details

Table 83. Jazz Pharmaceuticals Business Overview

Table 84. Jazz Pharmaceuticals Viral Vectors Gene Therapy Product

Table 85. Jazz Pharmaceuticals Revenue in Viral Vectors Gene Therapy Business (2020-2025) & (US$ Million)

Table 86. Jazz Pharmaceuticals Recent Development

Table 87. Dynavax Technologies Company Details

Table 88. Dynavax Technologies Business Overview

Table 89. Dynavax Technologies Viral Vectors Gene Therapy Product

Table 90. Dynavax Technologies Revenue in Viral Vectors Gene Therapy Business (2020-2025) & (US$ Million)

Table 91. Dynavax Technologies Recent Development

Table 92. Biogen Company Details

Table 93. Biogen Business Overview

Table 94. Biogen Viral Vectors Gene Therapy Product

Table 95. Biogen Revenue in Viral Vectors Gene Therapy Business (2020-2025) & (US$ Million)

Table 96. Biogen Recent Development

Table 97. Sarepta Therapeutics Company Details

Table 98. Sarepta Therapeutics Business Overview

Table 99. Sarepta Therapeutics Viral Vectors Gene Therapy Product

Table 100. Sarepta Therapeutics Revenue in Viral Vectors Gene Therapy Business (2020-2025) & (US$ Million)

Table 101. Sarepta Therapeutics Recent Development

Table 102. Gilead Sciences Company Details

Table 103. Gilead Sciences Business Overview

Table 104. Gilead Sciences Viral Vectors Gene Therapy Product

Table 105. Gilead Sciences Revenue in Viral Vectors Gene Therapy Business (2020-2025) & (US$ Million)

Table 106. Gilead Sciences Recent Development

Table 107. Research Programs/Design for This Report

Table 108. Key Data Information from Secondary Sources

Table 109. Key Data Information from Primary Sources

Table 110. Authors List of This Report

List of Figures

Figure 1. Viral Vectors Gene Therapy Picture

Figure 2. Global Viral Vectors Gene Therapy Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Viral Vectors Gene Therapy Market Share by Type: 2024 VS 2031

Figure 4. Retro Viral Vectors Features

Figure 5. Adeno-associated Virus Vectors Features

Figure 6. Other Viral Vectors Features

Figure 7. Global Viral Vectors Gene Therapy Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Viral Vectors Gene Therapy Market Share by Application: 2024 VS 2031

Figure 9. In Vivo Case Studies

Figure 10. Ex Vivo Case Studies

Figure 11. Viral Vectors Gene Therapy Report Years Considered

Figure 12. Global Viral Vectors Gene Therapy Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Viral Vectors Gene Therapy Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Viral Vectors Gene Therapy Market Share by Region: 2024 VS 2031

Figure 15. Global Viral Vectors Gene Therapy Market Share by Players in 2024

Figure 16. Global Top Viral Vectors Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vectors Gene Therapy as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Viral Vectors Gene Therapy Revenue in 2024

Figure 18. North America Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Viral Vectors Gene Therapy Market Share by Country (2020-2031)

Figure 20. United States Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Viral Vectors Gene Therapy Market Share by Country (2020-2031)

Figure 24. Germany Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Viral Vectors Gene Therapy Market Share by Region (2020-2031)

Figure 32. China Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Viral Vectors Gene Therapy Market Share by Country (2020-2031)

Figure 40. Mexico Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Viral Vectors Gene Therapy Market Share by Country (2020-2031)

Figure 44. Turkey Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Viral Vectors Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Amgen Revenue Growth Rate in Viral Vectors Gene Therapy Business (2020-2025)

Figure 48. Novartis Revenue Growth Rate in Viral Vectors Gene Therapy Business (2020-2025)

Figure 49. Orchard Therapeutics Revenue Growth Rate in Viral Vectors Gene Therapy Business (2020-2025)

Figure 50. Spark Therapeutics Revenue Growth Rate in Viral Vectors Gene Therapy Business (2020-2025)

Figure 51. Agc Biologics Revenue Growth Rate in Viral Vectors Gene Therapy Business (2020-2025)

Figure 52. Anges Revenue Growth Rate in Viral Vectors Gene Therapy Business (2020-2025)

Figure 53. Bluebird Bio Revenue Growth Rate in Viral Vectors Gene Therapy Business (2020-2025)

Figure 54. Jazz Pharmaceuticals Revenue Growth Rate in Viral Vectors Gene Therapy Business (2020-2025)

Figure 55. Dynavax Technologies Revenue Growth Rate in Viral Vectors Gene Therapy Business (2020-2025)

Figure 56. Biogen Revenue Growth Rate in Viral Vectors Gene Therapy Business (2020-2025)

Figure 57. Sarepta Therapeutics Revenue Growth Rate in Viral Vectors Gene Therapy Business (2020-2025)

Figure 58. Gilead Sciences Revenue Growth Rate in Viral Vectors Gene Therapy Business (2020-2025)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Viral Vectors Gene Therapy market? zhanKai

The top companies in the global Viral Vectors Gene Therapy market are Amgen、Novartis、Orchard Therapeutics.

Related Reports

Viral Vectors Gene Therapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Viral Vectors Gene Therapy was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-13
Pages: 109
USD 3950.00
(Single User License)
Global Viral Vectors Gene Therapy Market Insights, Forecast to 2030
Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
Published Date: 2024-04-10
Pages: 107
USD 4900.00
(Single User License)
Global Viral Vectors Gene Therapy Market Research Report 2024
Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
Published Date: 2024-01-17
Pages: 83
USD 2900.00
(Single User License)

Viral Vectors Gene Therapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Viral Vectors Gene Therapy was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-13
Pages: 109
USD 3950.00 (Single User License)
Global Viral Vectors Gene Therapy Market Insights, Forecast to 2030
Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
Published: 2024-04-10
Pages: 107
USD 4900.00 (Single User License)
Global Viral Vectors Gene Therapy Market Research Report 2024
Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
Published: 2024-01-17
Pages: 83
USD 2900.00 (Single User License)